These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 19494288

  • 1. Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells.
    Tripp CH, Sparber F, Hermans IF, Romani N, Stoitzner P.
    J Immunol; 2009 Jun 15; 182(12):7644-54. PubMed ID: 19494288
    [Abstract] [Full Text] [Related]

  • 2. NKT cell responses to glycolipid activation.
    Tefit JN, Davies G, Serra V.
    Methods Mol Biol; 2010 Jun 15; 626():149-67. PubMed ID: 20099127
    [Abstract] [Full Text] [Related]

  • 3. Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
    Bontkes HJ, Moreno M, Hangalapura B, Lindenberg JJ, de Groot J, Lougheed S, van der Vliet HJ, van den Eertwegh AJ, de Gruijl TD, von Blomberg BM, Scheper RJ.
    Clin Immunol; 2010 Sep 15; 136(3):364-74. PubMed ID: 20570567
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
    Ko SY, Lee KA, Youn HJ, Kim YJ, Ko HJ, Heo TH, Kweon MN, Kang CY.
    Eur J Immunol; 2007 Aug 15; 37(8):2127-37. PubMed ID: 17615581
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of marginal zone B lymphocytes in invariant NKT cell activation.
    Bialecki E, Paget C, Fontaine J, Capron M, Trottein F, Faveeuw C.
    J Immunol; 2009 May 15; 182(10):6105-13. PubMed ID: 19414762
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Inhibition of early tumor growth requires J alpha 18-positive (natural killer T) cells.
    Stewart TJ, Smyth MJ, Fernando GJ, Frazer IH, Leggatt GR.
    Cancer Res; 2003 Jun 15; 63(12):3058-60. PubMed ID: 12810627
    [Abstract] [Full Text] [Related]

  • 11. Comparative evaluation of CD8+CTL responses following gene gun immunization targeting the skin with intracutaneous injection of antigen-transduced dendritic cells.
    Gaffal E, Schweichel D, Tormo D, Steitz J, Lenz J, Basner-Tschakarjan E, Limmer A, Tüting T.
    Eur J Cell Biol; 2007 Dec 15; 86(11-12):817-26. PubMed ID: 16928407
    [Abstract] [Full Text] [Related]

  • 12. NKT and tolerance.
    Diana J, Beaudoin L, Gautron AS, Lehuen A.
    Methods Mol Biol; 2011 Dec 15; 677():193-206. PubMed ID: 20941612
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Selective ability of mouse CD1 to present glycolipids: alpha-galactosylceramide specifically stimulates V alpha 14+ NK T lymphocytes.
    Burdin N, Brossay L, Koezuka Y, Smiley ST, Grusby MJ, Gui M, Taniguchi M, Hayakawa K, Kronenberg M.
    J Immunol; 1998 Oct 01; 161(7):3271-81. PubMed ID: 9759842
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interview: glycolipid antigen presentation by CD1d and the therapeutic potential of NKT cell activation.
    Kronenberg M.
    J Vis Exp; 2007 Oct 01; (10):635. PubMed ID: 18989407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.